Since the National Institute on Aging and Alzheimer’s Association issued its 2011 guidelines delineating separate diagnostic recommendations for preclinical, mild cognitive impairment, and dementia stages, Alzheimer’s disease (AD) research has moved on. As a neurodegenerative syndrome, diagnosis initially hinged on the clinical picture, cognitive testing, and MRIs. More recently, however, this extremely complex disease continuum has come to be defined, primarily, by its biological manifestations.
In this article, Cerba Research’s Chief Science Officer Jérôme Sallette divulges how Cerba is using the latest trends in biomarkers to enable early intervention of Alzheimers.
Reach out to our experts and discover how we can help you advance your clinical trial